Ann: S&P DJI Announces September 2022 Quarterly Rebalance, page-76

First 76 Last

Share
Profile

Follow
volvoman

1,266 Posts.

302

03/09/22

08:48

Post #: 63498300
Share

Originally posted by Obe wan: ↑

The area which AVZ were provided the decree for the mining licence for , was the southern section I.e Roche Dure and up to the last bore collar in Carrier to the North

The northern section within Carrier past that bore collar ,
under the decree left the area as being an exploration licence : so I believe that will remain as is and only the Southern zone will transition through to full mining licence as this stage .

My belief is that the southern area was done and dusted and we could have just paid mining rights on that and moved on , but the Carrier area with regard to what CAMI had offered and actually breaching mining code , looked a bit off and likely opened up a few hurdles in actually progressing that area to licence , particularly considering the vultures whom were waiting on the sidelines peering in ; AJNs morphing from a rusty tin can into a company going to provide guidance in the DRC was pretty interesting timing.

imo negotiations have been finalised ; north will remain as exploration , but through the long dragged out saga , it’s likely some new terms providing tighter control than initally
dishes out by CD of CAMI.

what we should see now , is full transition to ML for Roche Dure and North remaining as exploration and that hatched area currently missing, returning as that .

Expand

Good God Man, Woman or Other ... you are simply amazing!

I tip my Volvo cap to you.

V.

AVZ Price at posting: 78.0¢ Sentiment: Buy Disclosure: Held
15 Upvote

0 Great analysis

Reply

Top Stories

CTT

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

AI stocks: What to expect in 2024-25

NWC

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

LRL

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

ATH

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability